ME Therapeutics Holdings Inc.
METX
CNSX
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Net Income | -964.10K | -891.70K | -856.90K | -838.10K | -950.70K |
| Total Depreciation and Amortization | 77.40K | 71.00K | 59.60K | 40.20K | 21.90K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.50K | 21.40K | 132.70K | 255.40K | 478.10K |
| Change in Net Operating Assets | 29.70K | 56.50K | 47.30K | -5.80K | -14.50K |
| Cash from Operations | -849.60K | -742.90K | -617.40K | -548.30K | -465.10K |
| Capital Expenditure | -61.60K | -147.50K | -152.70K | -120.20K | -114.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -40.90K | -40.90K | -48.80K | -48.80K | -7.90K |
| Cash from Investing | -102.50K | -188.40K | -201.50K | -169.00K | -121.90K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -65.90K | -65.50K | -54.30K | -38.00K | -21.70K |
| Issuance of Common Stock | 184.00K | 1.23M | 1.05M | 1.05M | 1.50M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -7.50K | -7.50K |
| Cash from Financing | 84.20K | 818.70K | 694.80K | 701.20K | 1.04M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -867.90K | -112.70K | -124.20K | -16.20K | 455.90K |